Blueprint Medicines Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Blueprint Medicines's estimated annual revenue is currently $445M per year.
- Blueprint Medicines received $345.0M in venture funding in March 2019.
- Blueprint Medicines's estimated revenue per employee is $973,742
- Blueprint Medicines's total funding is $259.8M.
- Blueprint Medicines has 457 Employees.
- Blueprint Medicines grew their employee count by 27% last year.
- Blueprint Medicines currently has 33 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Blueprint Medicines?
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients lives. We don't think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Timothy Labranche||Senior Director, Toxicologic Pathology|
|Scott Mulholland||Manager, Regulatory Affairs|
|Angela Pontrello||Director, Quality Control|
|Tuan Si||Vice President, Pharmacovigilance & Safety|
|Michael Nest||Associate Director||Email Available|
|Roan Martin||Senior Director, Quality Assurance||Email Available|
|Todd Billet||Director, Field Operations|
|Lauren Barnes||Senior Vice President, Market Access|
|Teresa Alvarez-Diez||Associate Director|
|Marta Murcia||Director, Strategic Alliances|
Blueprint Medicines News
A month has gone by since the last earnings report for Blueprint Medicines (BPMC). Shares have lost about 18.3% in that time frame, ...
WCM Investment Management LLC purchased a new stake in shares of Blueprint Medicines Corp (NASDAQ:BPMC) in the second quarter, ...
Traders following shares of Blueprint Medicines Corporation (NASDAQ:BPMC) may have noted that the stock most recently closed at 76.51.
Blueprint Medicines Funding
|2014-01-08||$25.0M||B||Nextech Invest Ltd||Article|
|2014-11-13||$50.0M||C||Partner Fund Management||Article|
|2016-12-07||$143.8M||Undisclosed||Goldman, Sachs & Co||Article|
|2016-12-14||$134.5M||Undisclosed||Goldman, Sachs & Co.||Article|
|2017-03-30||$230.0M||Undisclosed||Goldman, Sachs & Co||Article|
|2017-04-05||$215.6M||Undisclosed||Goldman, Sachs & Co||Article|
|2017-12-12||$316.2M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2017-12-14||$345.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2019-03-28||$345.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
Blueprint Medicines Executive Hires
|2012-11-14||Daniel S. Lynch||Chairman||Article|
|2013-09-18||Kyle Kuvalanka||Chief Business Officer||Article|
|2015-02-12||Anthony Boral||SVP Clinical Development||Article|
|2016-09-07||Tracey McCain||Chief Legal Officer/EVP||Article|
|2016-11-15||Marion Dorsch||Chief Scientific Officer||Article|
|2017-10-11||Christopher Murray||SVP Technical Operations||Article|
|2018-10-30||Christina Rossi||Chief Commercial Officer||Article|